Glass House Brands (GLAS) Preferred Stock Liabilities (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Preferred Stock Liabilities of $15.0 million for Q1 2026, up 503.62% year-over-year from $2.5 million in Q1 2025, and little changed quarter-over-quarter from $15.0 million in Q3 2025.
Glass House Brands (GLAS) Preferred Stock Liabilities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Preferred Stock Liabilities for 7 consecutive years, with $15.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Preferred Stock Liabilities rose 503.62% year-over-year to $15.0 million; the TTM figure through Mar 2026 stood at $15.0 million (up 503.62% YoY), while the FY2024 annual figure was $2.6 million, down 69.91% from the prior year.
- Preferred Stock Liabilities steadied at $15.0 million in Q1 2026 per GLAS's latest filing, from $15.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $15.0 million in Q3 2025 and bottomed at $2.5 million in Q1 2025.
- Historically, Preferred Stock Liabilities has averaged $7.4 million across 5 years, with a median of $8.4 million in 2022.
- Annual changes were most pronounced in 2022 — Preferred Stock Liabilities tumbled 99.32% — and 2026, when it surged 503.62%.
- Glass House Brands' Preferred Stock Liabilities stood at $8.6 million in 2022, then fell by 0.22% to $8.6 million in 2023, then tumbled by 69.91% to $2.6 million in 2024, then jumped by 481.62% to $15.0 million in 2025, then changed by 0.0% to $15.0 million in 2026.
- Business Quant data shows GLAS's Preferred Stock Liabilities at $15.0 million in Q1 2026, $15.0 million in Q3 2025, and $6.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Glass House Brands | 831.09 Mn | 812.54 Mn | 15.77 Mn | 77.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.00 Mn |
| Sep 30, 2025 | 15.00 Mn |
| Jun 30, 2025 | 6.75 Mn |
| Mar 31, 2025 | 2.49 Mn |
| Dec 31, 2024 | 2.58 Mn |
| Sep 30, 2024 | 2.98 Mn |
| Jun 30, 2024 | 5.83 Mn |
| Mar 31, 2024 | 8.58 Mn |
| Dec 31, 2023 | 8.57 Mn |
| Sep 30, 2023 | 10.90 Mn |
| Jun 30, 2023 | 8.60 Mn |
| Mar 31, 2023 | 8.60 Mn |
| Dec 31, 2022 | 8.59 Mn |
| Sep 30, 2022 | 8.23 Mn |
| Jun 30, 2022 | 2.76 Mn |
| Mar 31, 2022 | 2.76 Mn |
| Dec 31, 2021 | 2.76 Mn |
| Sep 30, 2021 | 2.76 Mn |
| Mar 31, 2021 | 402.50 Mn |
| Dec 31, 2020 | 402.50 Mn |